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Background There is concern that non-inferiority trials might be deliberately
designed to conceal that a new treatment is less effective than a
standard treatment. In order to test this hypothesis we performed a
meta-analysis of non-inferiority trials to assess the average effect
of experimental treatments compared with standard treatments.
Methods One hundred and seventy non-inferiority treatment trials published
in 121 core clinical journals were included. The trials were identi-
fied through a search of PubMed (1991 to 20 February 2009).
Combined relative risk (RR) from meta-analysis comparing experi-
mental with standard treatments was the main outcome measure.
Results The 170 trials contributed a total of 175 independent comparisons
of experimental with standard treatments. The combined RR for
all 175 comparisons was 0.994 [95% confidence interval (CI)
0.978–1.010] using a random-effects model and 1.002 (95% CI
0.996–1.008) using a fixed-effects model. Of the 175 comparisons,
experimental treatment was considered to be non-inferior in 130
(74%). The combined RR for these 130 comparisons was 0.995 (95%
CI 0.983–1.006) and the point estimate favoured the experimental
treatment in 58% (n¼ 76) and standard treatment in 42% (n¼ 54).
The median non-inferiority margin (RR) pre-specified by trialists
was 1.31 [inter-quartile range (IQR) 1.18–1.59].
Conclusion In this meta-analysis of non-inferiority trials the average RR com-
paring experimental with standard treatments was close to 1. The
experimental treatments that gain a verdict of non-inferiority
in published trials do not appear to be systematically less effective
than the standard treatments. Importantly, publication bias and
bias in the design and reporting of the studies cannot be ruled
out and may have skewed the study results in favour of the
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experimental treatments. Further studies are required to examine
the importance of such bias.
Keywords Non-inferiority, meta-analysis, systematic review
Introduction
Non-inferiority trials are increasingly published in the
medical literature, increasingly used in drug licensing
and have at the same time come under increased
scrutiny and criticism, up to the allegation that they
are unethical.1–13 A verdict of ‘non-inferiority’ leaves
readers with the impression that a new experimental
treatment is as good as an established standard treat-
ment and that the two can be used interchangeably.
However, in such trials, non-inferiority is statistically
accepted whenever an experimental treatment is
unlikely to be worse than an established treatment
by more than a pre-specified amount, the so-called
non-inferiority margin. If a relatively wide margin is
chosen, new treatments that are actually less benefi-
cial might wrongly be considered as equally effective.
This may lead to acceptance and use of new therapies
that are actually less effective in a clinically relevant
way.10,12
There is concern that non-inferiority trials might be
deliberately designed to conceal that a new treatment
is somewhat less effective than a standard treat-
ment.10,12 Systematic use of too-large non-inferiority
margins or systematic biases of design, conduct or
reporting of non-inferiority trials may skew results
in favour of new treatments.14–19 In this meta-
analysis we examined one type of systematic bias. If
trialists systematically compare slightly less effective
new treatments with standard treatments, the com-
bined results from a meta-analysis of many trials in
which experimental treatments gain a verdict of
non-inferiority, would be expected to favour the
standard treatment. In order to test this hypothesis,
we performed a meta-analysis of non-inferiority trials
published in clinical journals and assessed the average
effect of experimental treatments compared with
standard treatments. Importantly, the combined esti-
mate from the meta-analysis will not be influenced by
the choice of the non-inferiority margins.
Methods
Eligibility and search strategy
We searched for non-inferiority trials on 20 February
2009 using PubMed (National Library of Medicine)
with the text words ‘noninferiority’ or ‘non inferiority’
or ‘equivalence’ combined with the text words ‘clinic-
al trial’ or ‘trial’ or ‘trials’ or ‘study’ or ‘studies’, limit-
ing the search to publications from 1991 onwards.
The initial search was restricted to six general medi-
cine journals (Annals of Internal Medicine, BMJ, JAMA,
Lancet, New England Journal of Medicine and PLoS
Medicine). In a second step the search was extended
to include the other 115 journals included in
PubMed’s selection of core clinical journals (see
http://www.nlm.nih.gov/bsd/aim.html for a list of
these journals). Although equivalence trials (trials
that specify both a lower and an upper equivalence
margin)20,21 were not eligible for inclusion, we
included the term ‘equivalence’ in our search strategy
in order not to miss non-inferiority trials that had
been described as equivalence trials.
Study selection
All two-arm parallel group non-inferiority trials of an
experimental treatment compared with standard ther-
apy were included, independent of the intervention
examined in the trial. Articles that were published
electronically ahead of print were also considered.
Data extraction
The following information was extracted independ-
ently by two investigators (D.S. and R.M.): year of
publication, journal, subject area (cardiovascular
medicine, infectious diseases, obstetrics and gynaecol-
ogy, rheumatology, surgery or other), primary end-
point, non-inferiority margin for primary endpoint,
expected incidence of the primary endpoint in the
standard arm and the point estimate for the compari-
son of experimental with standard treatment. The pri-
mary endpoint was classified into three categories:
(i) mortality alone or as part of a combined endpoint;
(ii) clinical disease; and (iii) surrogate endpoint (ima-
ging or laboratory test). Disagreements were resolved
in consultation with a third investigator (O.D.). If
trials presented more than one primary endpoint,
the endpoint for which the sample size had been cal-
culated was used. If it was unclear for which end-
point sample size calculations were done, or if no
such calculations were reported, one of the primary
endpoints was randomly selected. In trials that
included several non-inferiority comparisons using
the same standard treatment, e.g. when testing two
dosages of an experimental therapy, one comparison
was selected at random and included in the analysis.
If a study reported both intention-to-treat- and per-
protocol analyses, the result used by the author to
determine whether the intervention was non-inferior
was extracted. If this was not clear, the per-protocol
results were used. The funding source was independ-
ently classified by two investigators (D.S. and O.D.) as
industry, public or mixed funding. The provision of
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study drugs by industry was considered as a source of
industry funding.
Data synthesis and analysis
The confidence intervals (CIs) and non-inferiority
margins reported by the investigators were used to
classify the results as superior, non-inferior, inconclu-
sive or inferior according to the definitions given
in the extension of the Consolidated Standards of
Reporting Trials (CONSORT) statement to non-
inferiority trials.9 Superiority was assumed if the
experimental treatment was significantly (P< 0.05)
more efficacious than the standard treatment.
Non-inferiority was assumed if the 95% CI did not
include the non-inferiority margin. Results were clas-
sified as inconclusive if the 95% CI included the
non-inferiority margin. Treatments were assumed to
be inferior if the entire 95% CI was significantly worse
than the non-inferiority margin.
Results of comparisons were expressed as ratio
measures, which we call relative risks (RRs) through-
out this article. If the trial reported risk ratios or
hazard ratios (HRs) or odds ratios (ORs) from statis-
tical models these were used in the analyses. For
trials that reported risk differences, we calculated
the risk ratio. For studies reporting continuous end-
points (e.g. blood pressure), results were converted to
ORs using the method described by Hasselblad and
Hedges,22 and the OR was then used in further cal-
culations. This method assumes logistic distributions
with equal variances in the two treatment groups.
Under this assumption the natural logarithm of the
OR equals a constant multiplied by the standardized
difference between means. If needed, the inverse of
the RR was calculated, so that ratios41 consistently
favoured the standard treatment and ratios <1 fa-
voured the experimental treatment. The RRs from in-
dividual studies were combined using random-effects
models. In addition to combining RRs for all studies,
we performed stratified meta-analyses according to
whether results were interpreted as inferior, non-
inferior or superior, by type of effect measure, by
type of endpoint, by source of funding, by journal
and according to whether the judgement of the
result was based on an intention-to-treat analysis or
not. In a random-effects meta-regression model we
analysed the influence of the source of funding.
Pre-specified non-inferiority margins were also ex-
pressed as RRs. Margins that were reported as a dif-
ference in incidence were converted to RR by dividing
the expected incidence of the primary endpoint in the
standard treatment arm plus (for morbidity or mor-
tality) or minus (for beneficial endpoints) the
pre-specified margin by the expected incidence of
the primary endpoint in the standard treatment
arm. For example, if the expected mortality rate in
the standard treatment arm was 10% and the
pre-specified margin was set at 2%, the margin con-
verted to an RR of 1.2 [(10þ 2)/10]. Margins could
not be expressed as RR for studies that did not report
the expected incidence, or studies reporting continu-
ous endpoints. We examined the median and the
distribution of non-inferiority margins and examined
whether margins differed across the subgroups of
trials mentioned above.
We compared the observed incidence of the primary
endpoint in the group that received standard treat-
ment with the expected incidence, as specified by
the trialists. The result was expressed as a ratio. If
needed, the inverse of this ratio was calculated, so
that ratios <1 consistently indicated that the standard
treatment performed better than was expected at the
design stage of the trial, and ratios41 indicated that
the standard treatment performed worse than was
expected. This ratio could not be calculated for studies
that did not report separately the expected, or the
observed incidence of the primary endpoint, or studies
reporting continuous endpoints.
Statistical analyses were done in Comprehensive
Meta-Analysis (version 2.0, Biostat, Englewood, NJ,
USA) and Stata (version 10.0, Stata Corporation,
College Station, TX, USA).
Results
Literature search and study characteristics
We identified 532 potentially eligible articles and
excluded 362 studies for the reasons shown in
Figure 1. A total of 170 studies, which were published
in 43 different journals, were included (see Appendix
Tables 1, 2 and 3 for bibliographic details45–197
available as supplementary data at IJE online). Five
articles reported the results for two separate compari-
sons. In total, 175 comparisons were therefore
included in the analyses. The oldest non-inferiority
study in our selection dates from 1993.23 Seventy-
eight percent of included studies date from 2004
onwards, reflecting an increase in non-inferiority
trials in the past 5 years.
The characteristics of the 170 non-inferiority trials
are described in Table 1. Of the general medical jour-
nals, the New England Journal of Medicine published the
largest number of non-inferiority trials; our search
found no non-inferiority trials in PLoS Medicine. Most
trials were from cardiovascular medicine (n¼ 47;
28%) or infectious disease (n¼ 43; 25%). Other
fields were obstetrics and gynaecology (7%), oncology
(6%), rheumatology (6%), surgery (5%), psychiatry
(3%), general medicine (3%), pulmonary medicine
(2%), gastroenterology (2%), anaesthesiology (1%),
intensive care medicine (1%) and neurology (1%).
The majority reported risk differences (n¼ 106;
61%); 36 studies reported continuous endpoints,
which were converted to ORs for the present analysis.
Figure 2 shows the type of endpoint, number of par-
ticipants, point estimate, CI and pre-specified margin
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for 33 comparisons that were reported on the RR
scale.
For 130 comparisons (74%), we considered the
experimental treatment to be non-inferior according
to the published criteria.9 Of note, in 6 of these 130
comparisons the authors deemed the experimental
treatment to be clinically inferior based on a second-
ary endpoint. For 27 comparisons (15%) results were
inconclusive, for 15 comparisons (9%) superior and
for 3 comparisons (2%) inferior. In 20 instances our
assessment differed from the authors’ verdict: in
9 instances we judged the result to be superior
where the authors’ verdict was non-inferior, in 6 in-
stances to be inconclusive as opposed to inferior and
once to be non-inferior instead of inferior. The au-
thors’ verdict was more favourable to the experimen-
tal treatment in four comparisons, each time judging
the result to be non-inferior instead of inconclusive.
Meta-analysis
The funnel plot showed a symmetrical distribution of
results around RR 1 (Figure 3). Forty-seven percent
of comparisons (n¼ 82) had a point estimate 41
(favouring standard treatment) and 53% (n¼ 93) <1
(favouring experimental treatment). Of the 130 com-
parisons judged to be non-inferior, the point estimate
favoured experimental treatment in 58% (n¼ 76) and
standard treatment in 42% (n¼ 54). The combined RR
for all 175 comparisons was 0.994 (95% CI
0.978–1.010) using a random-effects model and
1.002 (95% CI 0.966–1.008) using a fixed-effects
model. The combined RR for comparisons judged to
be non-inferior was 0.995 (95% CI 0.983–1.006). Table
2 shows stratified random-effects meta-analyses
according to trial result, measure of effect, type of
endpoint, source of funding, by two journal strata
and according to whether the judgement of the
result was based on an intention-to-treat analysis or
not. Using a random-effects model, the combined es-
timate for trials funded by industry was 0.978 (95%
CI 0.956–1.000). The combined result for trials funded
by public sources was 1.008 (95% CI 0.980–1.038).
These two estimates did not differ significantly
(P¼ 0.15 from random-effects meta-regression). All
meta-analyses were also performed using a
fixed-effects model and are presented in Appendix
Table 4 available as supplementary data at IJE
online. The main result and the results from the stra-
tified analyses were similar for the random- and
fixed-effects meta-analyses except for a difference in
the result stratified by funding source.
Non-inferiority margins
The margin was expressed as an RR for 33 compari-
sons and could be converted from a risk difference to
a RR for 91 comparisons. The median pre-specified
non-inferiority margin was 1.31 [inter-quartile range
(IQR) 1.18–1.59]. Stratified according to trial result,
the median margin was 1.42 (range 1.21–4.75) for 3
comparisons judged to be inferior, 1.33 (IQR
1.14–1.51) for 23 comparisons judged to be inconclu-
sive, 1.31 (IQR 1.19–1.59) for 92 comparisons judged
to be non-inferior and 1.45 (IQR 1.20–1.75) for 6
comparisons judged to be superior. Stratified by type
of endpoint the median margin was 1.34 (IQR 1.19–
1.50) for comparisons that had mortality as (part of a
combined) endpoint, 1.38 (IQR 1.20–1.70) for com-
parisons in which clinical disease was the endpoint
362 articles excluded
- not a randomized clinical trial (n = 230) 
- not a non-inferiority or equivalence trial (n = 53)
- symmetrical two-sided equivalence margin (n = 50) 
- trial of a diagnostic tool (n = 10) 
- data missing (n = 7)
- three study arms or more (n = 4)
- effect measure cannot be converted to an RR (n = 5)
- standard error equals zero (n = 2)
- sub-analysis of a trial that had already been included (n = 1)
532 potentially eligible articles identified
170 articles included
Two separate comparisons in one article (n=5)
175 comparisons included in analyses
Figure 1 Summary of the search strategy and study selection
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and 1.23 (IQR 1.15–1.35) for comparisons reported as
a surrogate endpoint. Stratified according to source of
funding the median margin was 1.30 (IQR 1.17–1.50)
for 62 trials funded by industry, 1.31 (IQR 1.12–1.63)
for 33 trials funded by public sources and 1.35
(IQR 1.23–1.55) for 19 trials with mixed funding.
The ratio of the observed and expected incidence of
the primary endpoint in the group that received
standard treatment could be calculated for 112 com-
parisons. Fifty-three percent of comparisons (n¼ 59)
had a ratio <1, indicating that the standard treatment
performed better than was expected at the design
stage of the trial and 46% (n¼ 51) 41, indicating
that the standard treatment performed worse than
was expected. Two ratios were exactly 1. The mean
ratio was 0.941 (95% CI 0.859–1.030), meaning that
on average the chosen standard treatments performed
slightly better than was estimated at the design stage
of the trials. Stratified by source of funding, this ratio
was 0.974 (95% CI 0.865–1.097) for 55 studies funded
by industry and 0.906 (95% CI 0.760–1.080) for
31 studies funded by public sources. These two esti-
mates did not differ significantly (P¼ 0.5 from t-test
for equality of means).
Discussion
In this meta-analysis of trials using a non-inferiority
design, experimental treatments were regarded as
non-inferior to standard treatments in the majority
of studies. The combined RR for these studies com-
paring experimental with standard treatments was
close to 1. For non-inferiority trials published in
core clinical journals, this finding contradicts the hy-
pothesis that new treatments that gain a verdict of
non-inferiority are systematically less effective than
standard treatments.
Our study has several strengths and limitations.
We aimed to include all the non-inferiority trials pub-
lished in these journals, irrespective of the type of
endpoints or measures of effect. We restricted the
search to the group of core clinical journals, as
defined in PubMed, which is the same group of jour-
nals as in the Abridged Index Medicus (AIM). This
selection covers a wide range of journals from many
clinical specialties. Our results may therefore be rep-
resentative for non-inferiority trials published in other
journals. However, external validity may be limited to
higher quality journals. If non-AIM journals are of
lower quality, the characteristics of non-inferiority
trials published in those journals might be different.
Furthermore, our search would have missed trials
that do not mention the non-inferiority design in
the abstract, the title or as a key word. The charac-
teristics of such trials might also differ.
We examined two aspects of non-inferiority trials:
first, we combined the results of a large number of
non-inferiority trials in a meta-analysis; secondly, we
examined the non-inferiority margins chosen by the
Table 1 Characteristics of the 170 non-inferiority trials
included in the meta-analysis
Study characteristics n Percentage
Journal
New England Journal of Medicine 33 19
Lancet 28 16
Circulation 11 6
Journal of the American
Medical Association
10 6
British Medical Journal 8 5
Obstetrics and Gynaecology 8 5
Paediatrics 8 5
Other (from 36 different
journals)
64 38
Field in medicine
Cardiovascular medicine 47 28
Infectious disease 43 25
Obstetrics and gynaecology 12 7
Oncology 10 6
Rheumatology 10 6
Surgery 9 5
Psychiatry 5 3
Other 34 20
Type of comparison
Drug 133 78
Procedure 23 14
Device 14 8
Source of funding
Industry 94 55
Public or charity 46 27
Mixed 19 11
Not reported 11 7
Median number of
participants per
comparison (range)a
467
(40–20 332)
Effect measurea
Risk difference 106 61
Ratio measure 33 19
HR 20
Risk ratio 7
OR 6
Continuous 36 21
Main analysis used to judge the resulta
Intention-to-treat analysis 95 54
Modified intention-to-treat
or per protocol analysis
80 46
aCharacteristics for 175 comparisons from the 170 trials.
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investigators. Importantly, the combined estimate
from the meta-analysis will not be influenced by the
choice of the non-inferiority margin. The combined
estimate will be influenced by the efficaciousness of
standard treatment. If the standard treatment is not
effective, the experimental treatment is in fact tested
against ‘placebo’ in a non-inferiority design. Although
we did not assess whether the chosen standard treat-
ment represented the best-available comparator, we
did assess how standard treatments performed in
view of what trialists had expected. On average, the
standard treatments performed slightly better than
was estimated at the design stage of the trials. Our
study did not address other important issues pertain-
ing to non-inferiority trials. For example, we did not
assess whether a non-inferiority trial was the appro-
priate design to use (or whether a superiority design
would have been more appropriate) or whether the
choice of the non-inferiority margin that was used
for the power calculation and statistical testing
Non-inferiority
margin
1.22
1.50
1.70
1.23
1.50
1.23
1.25
1.25
1.23
1.14
1.23
1.32
1.35
1.09
1.23
1.17
2.00
1.12
1.18
1.08
1.15
2.00
1.20
1.67
1.25
1.20
1.50
1.47
3.00
1.35
1.43
2.00
2.00
Endpoint type Participants (n) Relative risk (95% CI)
Olshansky29 mortality 988 0.67 (0.43 – 1.03)
Bousser30 clinical disease 4576 0.71 (0.39 – 1.30)
Agnelli31 clinical disease 2048 0.74 (0.50 – 1.09)
Fleshman32 clinical disease 863 0.84 (0.62 – 1.13)
Tebbe33 mortality 3089 0.85 (0.64 – 1.12)
Surgical therapy34 clinical disease 863 0.86 (0.63 – 1.17)
Schellhammer35 mortality 813 0.87 (0.74 – 1.03)
Twelves36 clinical disease 1987 0.87 (0.75 – 1.00)
Kitchener37 surrogate 240 0.88 (0.76 – 1.02)
Blazing38 mortality 3970 0.88 (0.71 – 1.09)
Cunningham-I39 mortality 964 0.89 (0.77 – 1.02)
Bozzetti40 mortality 618 0.89 (0.68 – 1.17)
Lincoff41 mortality 5966 0.92 (0.77 – 1.09)
Packer42 mortality 5770 0.94 (0.86 – 1.03)
Cunningham-II39 mortality 964 0.95 (0.82 – 1.10)
Willenheimer43 mortality 1002 0.97 (0.78 – 1.21)
Büller-I44 clinical disease 2904 0.98 (0.64 – 1.51)
Valgimigli45 surrogate 722 0.98 (0.93 – 1.04)
Yusuf46 mortality 20078 1.01 (0.90 – 1.13)
Sacco47 clinical disease 20332 1.01 (0.92 – 1.11)
Kim48 mortality 1433 1.02 (0.91 – 1.14)
El-Refaey49 clinical disease 1000 1.10 (0.79 – 1.54)
Home50 mortality 4447 1.11 (0.93 – 1.32)
Carrozza51 clinical disease 631 1.11 (0.71 – 1.74)
Stone52 clinical disease 9207 1.12 (0.97 – 1.29)
Cannon53 mortality 4162 1.19 (1.05 – 1.35)
Schröder54 mortality 234 1.23 (0.88 – 1.71)
Topol55 mortality 4809 1.26 (1.01 – 1.57)
Victor56 clinical disease 1090 1.35 (0.69 – 2.64)
Gülmezoglu57 surrogate 18442 1.39 (1.19 – 1.63)
Shiffman58 surrogate 1319 1.69 (1.32 – 2.18)
Steiner59 clinical disease 878 1.70 (1.09 – 2.66)
Büller-II44 clinical disease 2215 2.14 (1.21 – 3.78)
Favours
experimental
Favours
standard
0·5 2 510·2
Figure 2 Results for 33 comparisons from 31 trials in which the result was expressed as an RR. Point estimates, CIs
and non-inferiority margins (red lines, lighter gray in printed version) are shown
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Figure 3 Funnel plot of the standard error by the log RR
for 175 comparisons. Treatment on the X-axis and standard
error on the Y-axis. Bias would lead to an asymmetrical
appearance of the funnel plot
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made clinical sense. The non-inferiority margin is
often criticized as being arbitrary, unacceptably
wide or even fraudulent.8,10 The selection of the
non-inferiority margin should be based on a combin-
ation of statistical reasoning and clinical judge-
ment.9,24 Others have reviewed the rationale for the
size of the margins in non-inferiority trials.7,8 They
found that the majority of trials did not justify the
choice of the margin and that <20% reported a clinical
consideration. An in-depth analysis of each trial with
subject-matter knowledge on each topic would have
been required to judge whether the choice of the
margin was adequate. This was beyond the aim of
the present analysis.
Does our meta-analysis rebuke some of the criticism
aimed at non-inferiority trials? We found that the
combined RR for all studies was close to 1. This
contradicts the hypothesis that in non-inferiority
trials the experimental treatment is generally less ef-
fective than the standard treatment. We believe that
this is an important, reassuring finding, considering
the criticism that has been levelled at non-inferiority
trials.1–12 Several issues should nevertheless be con-
sidered when interpreting this result. First, current
standards for drug approval stipulate that a new
treatment should be better than placebo and (at
least) non-inferior to the established options. This
means that demonstrating non-inferiority can legally
suffice for the licensing of a new drug. The underlying
assumption is often that a ‘non-inferior’ treatment
has added value regarding other properties, such as
ease of use, lower costs or fewer adverse effects,
which might offset a small loss in efficacy.
Sometimes such superior properties, such as costs,
are self-evident and do not have to be demonstrated
in a trial. Claiming that an agent has less adverse
Table 2 Random-effects meta-analyses of 175 comparisons of experimental and standard treatments
from 170 non-inferiority trials
Number of comparisons RR (95% CI)
Overall analysis 175 0.994 (0.978–1.010)
Stratified analyses
By result
Result judged as inferior 3 2.255 (1.587–3.204)
Result judged as inconclusive 27 1.163 (1.102–1.227)
Result judged as non-inferior 130 0.995 (0.983–1.006)
Result judged as superior 15 0.694 (0.617–0.780)
By effect measure
Risk difference 106 0.996 (0.982–1.010)
Ratio measure 33 1.012 (0.958–1.069)
Continuous 36 0.954 (0.826–1.101)
By type of endpoint
Mortality as (part of a combined) endpoint 35 0.974 (0.935–1.015)
Clinical disease 81 0.998 (0.980–1.017)
Surrogate endpoint 59 1.000 (0.965–1.037)
By source of funding
Industry 96 0.978 (0.956–1.000)
Public source 48 1.008 (0.980–1.038)
Mixed 20 1.035 (0.972–1.103)
Not reported 11 1.018 (0.930–1.113)
By journal
N Engl J Med/Lancet/JAMA/BMJ/Ann Intern Med 87 0.990 (0.968–1.012)
Other journals 88 0.999 (0.976–1.023)
By the analysis used to judge the result
Intention-to-treat analysis 95 1.002 (0.977–1.028)
Modified intention-to-treat- or per-protocol analysis 80 0.989 (0.969–1.009)
All meta-analyses mentioned here were performed using a random-effects model. All meta-analyses were also
performed using a fixed-effects model and are shown in Appendix Table 4 available as supplementary data
at IJE online. The main result and the results from the stratified analyses were similar for the random- and
fixed-effects meta-analyses except for a difference in the result stratified by funding source.
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effects should however be based on evidence. A sep-
arate analysis of the adverse event data, analyses of
combined endpoints or a meta-analysis of several
trials might be appropriate and informative to dem-
onstrate superiority in this respect. Of the 175 com-
parisons in this meta-analysis, we considered the
experimental treatment to be non-inferior in 130
(74%) and superior in 15 (9%). Although in 6 of
these 145 comparisons the authors deemed the ex-
perimental treatment to be clinically inferior based
on a secondary endpoint, the majority of published
non-inferiority trials can be used to support the regis-
tration of a new treatment. The added value and
safety of these treatments may not always be
self-evident and may not always be demonstrated in
the trial. The follow-up time and the sample size of
trials are limited, making it improbable that rarer side
effects or long-term side effects are detected.
Secondly, for superiority trials, it has repeatedly
been described how the outcome may be skewed in
favour of the experimental treatment by making con-
venient choices when designing the study or reporting
or publishing the result. This may involve the choice
of (the dosage of) the comparator drug, the choice
of patients, endpoints or of the type of analysis.19,27
It may also involve selective reporting of data or chan-
ging the pre-specified endpoint after a study is com-
pleted.16 It is plausible that such mechanisms affect
the results of non-inferiority trials. In other words,
biased choices in study design and bias due to select-
ive reporting of outcomes may make it more likely
that an experimental treatment is considered
non-inferior after completion of the trial. We did
not have access to the study protocols of the included
articles and relied on what was reported as the pri-
mary endpoint. Also, we restricted our search to stu-
dies that have been published. Unpublished trials are
more likely to favour standard treatment.17 Therefore,
if publication bias would be an issue, our results
might be skewed in favour of experimental treat-
ments. All these potential sources of bias would
remain unnoticed in our meta-analysis. Although
the funnel plot showed a symmetrical distribution of
results around RR 1, this does not rule out biases.
This leaves the possibility that our finding of an over-
all RR close to unity is skewed in favour of experi-
mental treatment. The finding that studies sponsored
by industry were more likely to have results favouring
sponsored treatments is in line with other re-
ports.15,25,26 Systematic bias has been suggested as a
possible explanation. Our finding could also be due to
the play of chance.
Thirdly, the statistical verdict of non-inferiority per-
mits licensing of a drug even if the trial result shows
that it is somewhat less effective than standard.
Therefore, some treatments that are approved based
on non-inferiority testing may be less effective com-
pared with the standard therapy with respect to the
primary endpoint. A cascade of non-inferiority trials is
possible, in which each next experimental treatment
is slightly less effective than the previously estab-
lished ‘standard’. After several generations of
non-inferiority trials, ineffective interventions could
be licensed, leading to deteriorating patient care.4,11
This outcome has been called ‘bio-creep’.28 Our results
are relevant in this context. Our study showed that of
the 130 comparisons judged to be non-inferior, the
point estimate favoured the standard treatment in
42% of trials. Biocreep could occur if two or three
trials in succession belong to this 42% category and
if each next trial adopts the previously demonstrated
non-inferior treatment as the new active control treat-
ment. Importantly, our study provided no empirical
evidence for or against the existence of biocreep.
In conclusion, the number of non-inferiority trials
published in clinical journals has greatly increased.
We found that the experimental treatments that
gain a verdict of non-inferiority in trials published
in core clinical journals are not systematically less
effective than the standard treatments. Biases in
design, reporting and publication cannot be ruled
out and may have skewed the study results in
favour of experimental treatments. Continued vigi-
lance is required to assure that non-inferiority trials
are used appropriately.
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KEY MESSAGES
 There is a concern that non-inferiority trials might be deliberately designed to conceal that a new
treatment is less effective than a standard treatment. There is little empirical evidence at present to
support this notion, however.
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 The combined RR from 170 randomized trials using a non-inferiority design and published in core
clinical journals in recent years was close to 1, favouring neither the experimental nor the standard
treatment.
 In the majority of trials, the new treatments were considered to be non-inferior. For these trials the
combined RR was also close to 1.
 The experimental treatments that gain a verdict of non-inferiority do not, therefore, appear to be
systematically less effective than the standard treatments.
 The evidence from published non-inferiority trials might still be distorted by publication bias, or by a
biased choice of standard treatments. Further studies are required to clarify the risk of bias in
non-inferiority trials.
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